McDonald's Corp. (MCD) is the largest fast-food restaurant company in the world, with nearly 34,500 restaurants in 119 countries. McDonald's success was built on an idea of consistency. Consistency in food preparation, quality, and value. This consistency has been the model for other restaurant franchises for many years now. It has also led to a consistency of reliable and increasing dividend payments for the company's shareholders.
Utilizing our Dividend Safety scoring system, let's take a look at just how secure McDonald's current dividend payment is.
[ Enlarge Image ]
The only real concern that shows up is McDonald's most recent free cash flow payout ratio of 75%. This is considerably higher than its five-year average payout ratio of 60%. The increasing payout ratio is likely why investors received a 5% dividend increase this year versus the double digit increases they enjoyed in previous years. McDonald's cash position is also less than we like to see when compared to its annual dividend obligation, but it appears that management prefers the lower level of cash on hand as the current amount is typical when compared to historical levels.
Top 5 Food Companies To Watch In Right Now: Cintas Corp (CTAS)
Cintas Corporation (Cintas), incorporated November 13, 1986, provides specialized products and services to businesses of all types throughout the North America, Latin America, Europe and Asia. The Company operates in four segments: Rental Uniforms and Ancillary Products, Uniform Direct Sales, First Aid, Safety and Fire Protection Services, and Document Management Services. As of May 31, 2013, the Company provided products and services to over one million businesses. As of May 31, 2013, Cintas had approximately 8,200 local delivery routes, 446 operational facilities and eight distribution centers.
The Rental Uniforms and Ancillary Products operating segment consists of the rental and servicing of uniforms and other garments including flame resistant clothing, mats, mops and shop towels and other ancillary items. In addition to these rental items, restroom cleaning services and supplies and carpet and tile cleaning services are also provided within this operating segment. The Uniform Direct Sales operating segment consists of the direct sale of uniforms and related items and branded promotional products. The First Aid, Safety and Fire Protection Services operating segment consists of first aid, safety and fire protection products and services. The Document Management Services operating segment consists of document destruction, document imaging and document retention services.
Within the Rental Uniforms and Ancillary Products operating segment, Cintas provides its products and services to customers via local delivery routes originating from rental processing plants and branches. Within the Uniform Direct Sales and First Aid, Safety and Fire Protection Services operating segments, Cintas provides its products and services via its distribution network and local delivery routes or local representatives. Within the Document Management Services operating segment, Cintas provides its services via local service routes originating from document management branches and document retent! ion facilities. The Company operates five manufacturing facilities, which provide for standard uniform needs.
Advisors' Opinion:- [By Roberto Pedone]
Another earnings short-squeeze prospect is business support services player Cintas (CTAS), which is set to release numbers on Thursday after the market close. Wall Street analysts, on average, expect Cintas to report revenue of $1.10 billion on earnings of 63 cents per share.
The current short interest as a percentage of the float for Cintas stands at 5.6%. That means that out of the 102.38 million shares in the tradable float, 5.70 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 2.5%, or by about 136,000 shares. If the bears get caught pressing their bets into a strong quarter, then shares of CTAS could move up sharply higher post-earnings as the bears move to cover some of those bets.
From a technical perspective, CTAS is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last six months, with shares moving higher from its low of $42.35 to its recent high of $50.80 a share. During that uptrend, shares of CTAS have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CTAS within range of triggering a big breakout trade post-earnings.
If you're bullish on CTAS, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $61 to $62.27 a share and then once it takes its 52-week high at $50.80 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 458,136 shares. If that breakout hits, then CTAS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $60 to $65 a share.
I would simply avoid CTAS or look for short-biased trades if after earnings it fails to trigge
- [By Damian Illia]
As we can see, the firm has a higher ROE than Amrep Corporation (AXR) but is well below the one registered by US Ecology Inc. (ECOL) and Cintas Corporation (CTAS).
- [By Mike Deane]
After the closing bell on Monday, business services company Cintas Corporation (CTAS) released its fiscal 2015 first quarter results, with revenues coming in basically flat compared to last year’s Q1, while adjusted EPS came in higher.
CTAS’s�Earnings in Brief
Cintas�reported second quarter revenues of $1.102 billion, up 0.2% over last year’s Q1 revenues of $1.100 billion. Adjusted�earnings for the quarter came in at $92.4 million, or 78 cents per share, a significant gain over last year’s Q1 figures of $76.5 million, or 62 cents per share. The company�� results met analysts’ revenue expectations of $1.1 billion and EPS beat the 75 cent estimate. Looking ahead, Cintas sees FY2015 earnings in the range of $3.20-$3.29 on revenue in the range of $4.4 billion to $4.75 billion. Analysts are expecting EPS of $3.09 on revenue of $4.50 billion.CEO Commentary
Cintas CEO Scott D. Farmer released the following comments: “Our first quarter results reflect the continued good execution by our employees, who we call partners. We have focused on selling good, profitable business over the past few years, as well as managing our cost structure and continuously improving the efficiency of our processes. This focus has resulted in improved margins and better customer retention.��/p>
CTAS’s Dividend
Cintas made no mention of its annual dividend, which was to be expected as the company normally declares a dividend raise in mid-to-late October. CTAS paid its most recent annual dividend of 77 cents on December 11, 2013. We expect the company to announce a higher dividend within the coming weeks.
Stock Performance
CTAS stock was up 55 cents, or 0.83%, in after hours trading. YTD, the stock is up 12.21%.
CTAS Dividend SnapshotAs of Market Close on September 29, 2014
Click here to see the complete history of CTAS dividends.
- [By Saibus Research]
WY and the majority of the timber, forest and paper products companies have a track record of unimpressive returns on capital, cyclical revenue and profit trends, heavy use of capital expenditures, and significant environmental regulation. We also think that WY's conversion to a REIT was a mistake. Morningstar Investment Research's Timber, Forest and Paper Products analyst Dan Rohr said it best when he rated WY and its Timber REIT peers Rayonier (RYN), Potlatch (PCH) and Plum Creek (PCL) as not possessing any economic moat. That probably explains why we only have an ancillary exposure to this industry for our proprietary portfolio based on our holdings in Brookfield Infrastructure (BIP) and Cintas (CTAS). Brookfield's Timber segment only accounts for 5% of its Fund Flows from operations and Cintas's document management business is suffering from reduced prices on recycled paper. At least Cintas Document Management only accounts for 8% of Cintas's revenue.
Top Quality Stocks To Watch For 2015: Globe Specialty Metals Inc.(GSM)
Globe Specialty Metals, Inc., together with its subsidiaries, produces and sells silicon metal and silicon-based alloys in North America, Europe, South America, and Asia. The company primarily offers silicon metal that is used as a raw material for silicone compounds, aluminum, and polysilicon. It also produces silicon-based alloys, such as ferrosilicon; magnesium-ferrosilicon-based alloys known as nodularizers; ferrosilicon-based alloys known as inoculants; calcium silicon alloys; and cored-wire silicon-based alloy products, as well as carbon electrodes, silica fume, and fines. The silicon-based alloy products are used as raw materials for steel, automotive components, and ductile iron. In addition, the company processes and supplies specialty metallurgical coal to other silicon and silicon-based alloy producers. Its customers include silicone chemical, aluminum, and steel manufacturers; auto companies and their suppliers; ductile iron foundries; manufacturers of photovol taic solar cells and computer chips; and concrete producers. The company was formerly known as International Metal Enterprises, Inc. and changed its name to Globe Specialty Metals, Inc. in November 2006. Globe Specialty Metals, Inc. was incorporated in 2004 and is headquartered in New York, New York.
Advisors' Opinion:- [By Marc Bastow]
Silicon metals and alloys producer Globe Specialty Metals (GSM) raised its quarterly dividend 7.1% to 7.5 cents per share, payable March 12 to shareholders of record as of Feb. 26.
GSM Dividend Yield: 1.65%
Top Quality Stocks To Watch For 2015: Constellation Brands Inc (STZ)
Constellation Brands, Inc. produces and markets alcoholic beverages primarily in the United States, Canada, and New Zealand. It offers wine, spirits, and imported beer. The company?s Constellation Wines North America segment produces, markets, and exports wine, as well as sells various wine brands across various categories, including table wine, sparkling wine, and dessert wine. It offers wine under various brands, which include Robert Mondavi Brands, Clos du Bois, Blackstone, Estancia, Arbor Mist, Toasted Head, Simi, Black Box, Ravenswood, Rex Goliath, Kim Crawford, Franciscan Estate, Wild Horse, Ruffino, Nobilo, Mount Veeder, Inniskillin, and Jackson-Triggs; and spirits under various brands, including SVEDKA Vodka, Black Velvet Canadian Whisky, and Paul Masson Grande Amber Brandy. This segment also produces and markets wine kits and beverage alcohol refreshment drinks in Canada. The company?s Crown Imports segment imports, markets, and sells beer under the Modelo Brands, which include Corona Extra, Corona Light, Coronita, Modelo Especial, Pacifico, Negra Modelo, and Victoria, as well as the St. Pauli Girl and Tsingtao brands in the United States. The company sells its products through wholesale distributors, as well as state and provincial alcoholic beverage control agencies in North America; and directly to retailers or through wholesalers and importers in New Zealand. Constellation Brands, Inc. was founded in 1945 and is headquartered in Victor, New York.
Advisors' Opinion:- [By Monica Gerson]
Constellation Brands (NYSE: STZ) is expected to report its Q1 earnings at $0.93 per share on revenue of $1.43 billion.
The Greenbrier Companies (NYSE: GBX) is projected to report its Q3 earnings at $0.74 per share on revenue of $571.07 million.
- [By Caroline Bennett]
Lately, liquor company Constellation Brands (NYSE: STZ ) has been reaching for the stars to try to expand its brand, specifically into the beer market. In its most recent earnings release, the company saw its share of misses, but as CEO Rob Sands notes, the acquisition of beer distributor Grupo Modelo's U.S. branch was definitely a bright spot.
Top Quality Stocks To Watch For 2015: NanoViricides Inc (NNVC)
NanoViricides, Inc., incorporated on April 1, 2005, is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company�� drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. As of June 30, 2012, the Company had six drug development programs: Oral FluCideTM, against all Influenzas; a Piggy-back version of Flucide for hospitalized patients; nanoviricide eye drops against adenoviral EKC and herpes keratitis; HIVCide - I against HIV/AIDS; HerpeCide - I skin cream formulation for herpes cold sores and genital warts, and DengueCide, a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS). As of June 30, 2012, it had engaged in organizational activities, sourcing compounds and materials, developing novel compounds and nanomaterials, and experimentation with studies on cell cultures and animals. In September 2011, NanoViricides Inc's Inno-Haven LLC acquired a light industrial building.
The Company's product development programs are divided into three sectors: commercially important diseases, neglected tropical diseases (NTD��) and biosecurity/biodefense, and advanced technologies. The Company has collaborations with KARD Scientific, Inc., MA. and Southern Research Institute, AL for influenza viruse! s; National (Central) Institute of Hygiene and Epidemiology (NIHE) (Vietnam), for H5N1 avian flu; The Long Island Jewish Medical System, Feinstein Institute of Medical Research (LIJMS), NY and TheVac, LLC. for viral diseases of the eye (adenoviruses, herpesviruses - epidemic kerato-conjunctivitis (EKC), Herpes Keratitis); TheVac, LLC and Northeastern Ohio Medical University (NEOMED) for herpes virus infections; University of California at Berkeley for dengue hemorrhagic fever viruses; Center for Disease Control and Prevention (CDC) and National (Central) Institute of Hygiene and Epidemiology for rabies virus. The Company has developed lead drug candidates against a number of viral diseases.
The Company had consolidated all of its influenza drug programs into a single pan-influenza FluCide program. It is developing a single drug for all influenzas, whether pandemic, epidemic, seasonal, novel, emerging, human, swine, or avian. It is developing a nanoviricide against adenoviral EKC. The nanoviricide eye drug candidate is formulated as simple eye drops. It is developing an anti-HSV nanoviricide skin cream formulation for direct application to the lesions. It has designed the anti-HIV nanoviricides using rational drug design principles. The ligands it has designed in the case of HIV-1 are thought to be broadly neutralizing. In-silico modeling indicates that its ligands dock to the conserved CD4 binding site of gp120 of HIV-1. The Company is working on developing anti-Dengue therapeutics. Dengue is an important NTD. Its RabiCide program has resulted in candidates that have enabled survival of 20% to 30% of infected animals after disease has set in, using a particular animal model.
The Company competes with Roche, Glaxo SmithKline, BioCryst Pharmaceuticals, Inc., Gilead, Bristol-Myers Squibb Company (BMS), Roche, Boehringer Ingelheim, Merck & Co., Inc. (Merck), Valeant, Schering, Pharmassett, Vertex, Intermune, Achillion and Novartis.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 nano-biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.
If you take a look at the chart for Nanoviricides, you'll notice that this stock has recently formed a double bottom chart pattern at $4.55 to $4.52 a share. Following that bottom, shares of NNVC have now started to uptrend and move within range of triggering a big breakout trade. That trade will hit if NNVC manages to take out the upper-end of its recent sideways trading chart pattern, which has seen NNVC trend between $4.55 and $5.74 a share.
Traders should now look for long-biased trades in NNVC if it manages to break out above some near-term overhead resistance levels at Friday's high of $4.94 a share to its 50-day moving average of $5.28 a share, and then once it takes out some more key overhead resistance levels at $5.72 to $5.74 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 234,994 shares. If that breakout triggers soon, then NNVC will set up to re-test or possibly take out its next major overhead resistance levels at $6.50 to its 52-week high at $7.59 a share.
Traders can look to buy NNVC off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.55 to $4.52 a share. One can also buy NNVC off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Quality Stocks To Watch For 2015: Auxilio Inc (AUXO)
Auxilio, Inc. (Auxilio), incorporated on August 29, 1995, is engaged in the business of providing fully outsourced print management services to the healthcare industry. The Company is engaged in the business of providing fully-outsourced managed print services to the healthcare industry, working exclusively with hospitals throughout the United States. It provides solutions, a program and savings. It helps hospitals and health systems reduce expenses and create manageable, dependable document image management programs by managing their back-office processes. The process is initiated through a detailed assessment. The assessment is a strategic, operational and financial analysis that is performed at the customer�� premises using a combination of processes and technology for data collection and report generation. The Company�� customers include hospitals and integrated health delivery networks (IDN). Its subsidiaries include Auxilio Solutions, Inc. and e-Perception Technologies, Inc.
The Company helps hospitals and health systems to create image management programs by managing their back-office processes. The process is initiated through a detailed Image Management Assessment (IMA). The IMA is a strategic, operational and financial analysis that is performed at the customer�� premises using a combination of processes and Web-based technology for data collection and report generation. After the assessment and upon engagement, it charged the customer on a per print basis.
The Company competes with Xerox, Canon, Konica Minolta, Ricoh and Sharp.
Advisors' Opinion:- [By CRWE]
Today, AUXO surged (+3.26%) up +0.030 at $.950 with�200 shares in play thus far (ref. google finance Delayed: 9:30AM EDT August 23, 2013).
AUXILIO, Inc. previously reported financial results for its quarter ended June 30, 2013.
For the three months ended June 30, 2013, AUXILIO reported that recurring service revenues increased by $1.4 million from new contracts closed between May 2012 and April 2013; however revenues were $9.8 million, a decrease of 8% when compared to revenues of $10.7 million in the same period of 2012, due to a drop in equipment revenue. Equipment sales were $800,000 as compared to $3.1 million for the same period in 2012. Cost of revenues were $8.2 million for the three months ended June 30, 2013, as compared to $9.3 million for the same period in 2012. This drop was due to the drop in equipment sales offset by additional staffing and service costs from the higher recurring service revenue. Gross profit for the second quarter of 2013 was $1.6 million, or 17% of sales, compared to $1.4 million, or 13% of sales, for the same period of 2012. This improvement is a direct result of the large growth in new facilities that we added in 2012 coupled with the reduction in costs as AUXILIO�� program matures within these new accounts.
Top Quality Stocks To Watch For 2015: DexCom Inc.(DXCM)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company offers FDA approved SEVEN, which includes a disposable sensor that can be inserted by a patient and used continuously for up to seven days; a transmitter; and a small handheld receiver. Its SEVEN system also received CE Mark approval for commercialization in the European Union and the countries in Asia and Latin America that recognize the CE Mark. The company also provides the SEVEN PLUS, which incorporates additional user interface and algorithm enhancements that are intended to make its glucose monitoring function customizable. Its SEVEN PLUS has FDA and CE Mark approvals. DexCom has a collaboration agreement with Edwards Lifesciences LLC to develop products for conti nuously monitoring blood glucose levels in patients hospitalized for various conditions. It also has development agreement with Insulet Corporation to integrate its continuous glucose monitoring technology into Insulet?s wireless, handheld OmniPod System Personal Diabetes Manager; and a joint development agreement with Animas Corporation to integrate its continuous glucose monitoring technology into Animas insulin pumps. The company was founded in 1999 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Motley Fool Staff]
If we hope to halt or reverse those numbers, we'll need to approach patient care more holistically, and that could mean looking beyond drug therapies toward Dexcom's� (NASDAQ: DXCM ) continuous glucose monitoring sensors. Those sensors track and trend glucose levels, and alert patients when levels reach certain levels. By more accurately monitoring and treating these levels, patients might delay disease progression. That, in fact, could already be happening. Dexcom's sales jumped 60% in the past year to $68 million in the third quarter. But there's much work still to be done. Industry watchers estimate less than half of type 1 diabetics�and an even smaller percentage of type 2 patients�use monitors or insulin pumps to manage their disease.�
- [By Sean Williams]
Where's the beef, DexCom?
Sometimes a company's products make a lot of sense on paper, but the practical application doesn't go nearly as smoothly. This is how I'd describe medical monitoring device maker DexCom (NASDAQ: DXCM ) , which has an array of glucose monitoring devices to help diabetes patients better manage their disease. Make no mistake about it; the number of diabetes diagnoses in this country is rising in accord with our obesity rate. Therefore, a company like DexCom, which makes the DexCom G4 System monitor, could be a big hit, and certainly has a wide enough audience to cater to.
Top Quality Stocks To Watch For 2015: Somaxon Pharmaceuticals Inc.(SOMX)
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment medical conditions in the central nervous system therapeutic area. Its product includes Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance. The company sells its products to wholesale distributors in the United States. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Diego, California.
Advisors' Opinion:- [By CRWE]
Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, will release its financial results for the third quarter ended September 30, 2012 on Wednesday, October 31, 2012 after the close of the U.S. financial markets.
No comments:
Post a Comment